The invention concerns erythrocytes containing 5-fluorouracil, optionally associated with other active principles such as oxaliplatinum or another platinum derivative for anticancer therapy. The erythrocytes may have been subjected to a chemically or thermally denaturing treatment to promote their recognition by erythrophagocytic cells. The invention also concerns a drug produced from same, useful for treating primitive or secondary 5-FU-sensitive cancers, in particular secondary cancers present in the liver, the spleen, the lungs, the lymph nodes.
展开▼
